Instil Bio, Inc. Annual Report: A Year in Review

I’ve put together this guide to help you understand how Instil Bio performed this year. My goal is to turn complex filing information into plain English so you can decide if this company fits your investment goals.

1. What does the company do and how did they perform?

Instil Bio is currently in a total strategic transition. They have stopped all internal research and development and currently earn no money from product sales. The company has shifted from a drug developer to a holding entity looking for a "reverse merger" or a new business to acquire.

The defining event of the year was the January 2026 decision to stop developing their lead drug candidate, AXN-2510. This followed the earlier cancellation of their cell therapy programs. By clearing their pipeline, the company cut its research costs. However, it also removed its only path to selling products, leaving the company as a "shell" searching for a new purpose.

2. Financial performance

Because the company earns no revenue, its performance is defined by how much cash it spends and how it preserves what remains. For the year ending June 30, 2025, the company lost about $48.2 million, mostly from administrative costs and closing down clinical trials. While their spending has dropped, the company remains high-risk. Auditors have flagged "substantial doubt" about the company’s ability to stay in business. Without a successful merger or acquisition, they will likely run out of cash within 12 to 18 months, forcing them to shut down.

3. Major wins and challenges

• The Challenge: The company is essentially a blank slate. With no active drug trials, the company’s value depends almost entirely on its cash and its ability to complete a deal. There is no underlying business generating value today.
• The Strategy: Management is in "search mode," using their remaining cash to find a private company to acquire. This is risky. They must find a target that is scientifically sound and willing to use a public shell to go public. They are also competing against other cash-rich shell companies for these deals.

4. Financial health

As of June 30, 2025, Instil Bio held about $72.5 million in cash and short-term investments. Their market value is roughly $83.4 million. This means the stock trades very close to the value of the cash they hold, leaving little room for future growth. They keep their money in safe, low-yield U.S. Treasury securities. However, every dollar spent on legal and administrative fees to find a new partner reduces the cash available for the future.

5. Key risks

Investing in Instil Bio is a speculative bet on management’s ability to close a deal.

• Going Concern Risk: Auditors warn that current cash will not last indefinitely. The company must find a new path soon to avoid running out of money.
• No Active Pipeline: The company has no drugs or data that could generate future revenue. The stock price depends entirely on market hopes for a future deal.
• Competition: The market for reverse mergers is crowded. Better private companies often choose traditional IPOs or sales to big pharmaceutical firms.
• Dilution: If they find a target, they will likely issue more shares to pay for it. This will reduce your ownership percentage in the company.

Final Thought for Investors: Instil Bio is no longer a traditional biotech company; it is a cash-holding entity searching for a new identity. Before considering an investment, ask yourself if you are comfortable betting on management’s ability to successfully navigate a complex merger process. If you are looking for a company with active products or revenue, this is likely not the right fit for your portfolio.